Search

Your search keyword '"Susan Stonehouse-Lee"' showing total 13 results
Start Over Author "Susan Stonehouse-Lee" Search Limiters Available in Library Collection
13 results on '"Susan Stonehouse-Lee"'

1. Supplemental Figure 1 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Total amount of cfDNA extracted from each patient sample

Published
2023
Full Text
View/download PDF

2. Supplemental Table 5 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Available therapies and clinical trials

Published
2023
Full Text
View/download PDF

3. Supplemental Table 6 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Allelic fractions for all variants detected in tDNA and ctDNA* in patients for whom both plasma and tissue samples were obtained (n=50)

Published
2023
Full Text
View/download PDF

4. Supplemental Table 4 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Summary of driver and resistance mutations in EGFR and ALK detected in ctDNA, tDNA, and both ctDNA and tDNA

Published
2023
Full Text
View/download PDF

5. Supplemental Table 2 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Tissue next-generation sequencing gene coverage. A: Illumina TruSeq panel (47 genes), and B: Penn Precision Panel (20 genes)

Published
2023
Full Text
View/download PDF

6. Supplemental Table 7 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Analysis of discordant EGFR driver and resistance mutations detected in tDNA or ctDNA

Published
2023
Full Text
View/download PDF

7. Supplemental Table 3 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

All mutations detected in patient ctDNA (n=102)

Published
2023
Full Text
View/download PDF

8. Supplemental Table 1 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Circulating tumor DNA next-generation sequencing gene coverage

Published
2023
Full Text
View/download PDF

9. Data from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Erica L. Carpenter, Anil Vachani, Corey Langer, Elizabeth Gilbert, Victoria E. Sherry, Susan Stonehouse-Lee, Stephen Bagley, Roger B. Cohen, Christine Ciunci, Evan Alley, John A. Kosteva, Charu Aggarwal, Joshua Bauml, Tracey L. Evans, Jennifer D. Morrissette, David B. Lieberman, David Balli, Ryan Fan, Samantha L. Savitch, Andrea B. Troxel, Stephanie S. Yee, and Jeffrey C. Thompson

Abstract

Purpose: The expanding number of targeted therapeutics for non–small cell lung cancer (NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform serially and often yield inadequate DNA for next-generation sequencing (NGS). We evaluated the feasibility of using cell-free circulating tumor DNA (ctDNA) NGS as a complement or alternative to tissue NGS.Experimental Design: A total of 112 plasma samples obtained from a consecutive study of 102 prospectively enrolled patients with advanced NSCLC were subjected to ultra-deep sequencing of up to 70 genes and matched with tissue samples, when possible.Results: We detected 275 alterations in 45 genes, and at least one alteration in the ctDNA for 86 of 102 patients (84%), with EGFR variants being most common. ctDNA NGS detected 50 driver and 12 resistance mutations, and mutations in 22 additional genes for which experimental therapies, including clinical trials, are available. Although ctDNA NGS was completed for 102 consecutive patients, tissue sequencing was only successful for 50 patients (49%). Actionable EGFR mutations were detected in 24 tissue and 19 ctDNA samples, yielding concordance of 79%, with a shorter time interval between tissue and blood collection associated with increased concordance (P = 0.038). ctDNA sequencing identified eight patients harboring a resistance mutation who developed progressive disease while on targeted therapy, and for whom tissue sequencing was not possible.Conclusions: Therapeutically targetable driver and resistance mutations can be detected by ctDNA NGS, even when tissue is unavailable, thus allowing more accurate diagnosis, improved patient management, and serial sampling to monitor disease progression and clonal evolution. Clin Cancer Res; 22(23); 5772–82. ©2016 AACR.

Published
2023
Full Text
View/download PDF

10. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Samantha L. Savitch, Jeffrey C. Thompson, Christine Ciunci, Stephanie S. Yee, John A. Kosteva, Erica L. Carpenter, David B. Lieberman, Ryan Fan, Victoria Sherry, Anil Vachani, Evan W. Alley, Elizabeth Gilbert, Susan Stonehouse-Lee, David Balli, Andrea B. Troxel, Charu Aggarwal, Stephen J Bagley, Corey J. Langer, Joshua Bauml, Roger B. Cohen, Jennifer J.D. Morrissette, and Tracey L. Evans

Subjects
Adult, Male, 0301 basic medicine, Cancer Research, Lung Neoplasms, Genotype, medicine.medical_treatment, Biology, Bioinformatics, Somatic evolution in cancer, Article, Circulating Tumor DNA, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, medicine, Carcinoma, Humans, Prospective Studies, Lung cancer, Genotyping, Aged, Aged, 80 and over, High-Throughput Nucleotide Sequencing, Cancer, DNA, Neoplasm, Middle Aged, medicine.disease, Resistance mutation, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Cancer research, Female
Abstract

Purpose: The expanding number of targeted therapeutics for non–small cell lung cancer (NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform serially and often yield inadequate DNA for next-generation sequencing (NGS). We evaluated the feasibility of using cell-free circulating tumor DNA (ctDNA) NGS as a complement or alternative to tissue NGS. Experimental Design: A total of 112 plasma samples obtained from a consecutive study of 102 prospectively enrolled patients with advanced NSCLC were subjected to ultra-deep sequencing of up to 70 genes and matched with tissue samples, when possible. Results: We detected 275 alterations in 45 genes, and at least one alteration in the ctDNA for 86 of 102 patients (84%), with EGFR variants being most common. ctDNA NGS detected 50 driver and 12 resistance mutations, and mutations in 22 additional genes for which experimental therapies, including clinical trials, are available. Although ctDNA NGS was completed for 102 consecutive patients, tissue sequencing was only successful for 50 patients (49%). Actionable EGFR mutations were detected in 24 tissue and 19 ctDNA samples, yielding concordance of 79%, with a shorter time interval between tissue and blood collection associated with increased concordance (P = 0.038). ctDNA sequencing identified eight patients harboring a resistance mutation who developed progressive disease while on targeted therapy, and for whom tissue sequencing was not possible. Conclusions: Therapeutically targetable driver and resistance mutations can be detected by ctDNA NGS, even when tissue is unavailable, thus allowing more accurate diagnosis, improved patient management, and serial sampling to monitor disease progression and clonal evolution. Clin Cancer Res; 22(23); 5772–82. ©2016 AACR.

Published
2016
Full Text
View/download PDF

11. P3.02c-069 Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Author

Evan W. Alley, Faith Mutale, Gloria Dilullo, Roger B. Cohen, Tracey L. Evans, Victoria Sherry, Stephen J Bagley, Corey J. Langer, Joshua Bauml, Charu Aggarwal, Susan Stonehouse-Lee, Beth Eaby-Sandy, John A. Kosteva, Anil Vachani, Shawn Kothari, Jeffrey C. Thompson, Christine Ciunci, and Elizabeth Gilbert

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, non-small cell lung cancer (NSCLC), Nivolumab, Neutrophil to lymphocyte ratio, medicine.disease, business
Published
2017
Full Text
View/download PDF

12. P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab

Author

Joshua Bauml, Susan Stonehouse-Lee, Faith Mutale, Tracey L. Evans, John A. Kosteva, Elizabeth Gilbert, Beth Eaby-Sandy, Victoria Sherry, Stephen J Bagley, Charu Aggarwal, Evan W. Alley, Jeffrey C. Thompson, Christine Ciunci, Gloria Dilullo, Corey J. Langer, Roger B. Cohen, Anil Vachani, and Shawn Kothari

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Immune system, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Nivolumab, Adverse effect, business, 030215 immunology
Published
2017
Full Text
View/download PDF

13. P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)

Author

Charu Aggarwal, Tracey L. Evans, John A. Kosteva, Susan Stonehouse-Lee, Faith Mutale, Beth Eaby-Sandy, Anil Vachani, Joshua Bauml, Corey J. Langer, Elizabeth Gilbert, Shawn Kothari, Gloria Dilullo, Roger B. Cohen, Jeffrey C. Thompson, Christine Ciunci, Stephen J Bagley, Victoria Sherry, and Evan W. Alley

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Nivolumab, business
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results